ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Safety"

  • 2018 American Transplant Congress

    Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study

    S. Mulgaonkar,1 Y. Qazi,1 D. Kim,1 V. Peddi,1 K. McCague,2 D. Patel,2 A. Wiseman.1

    1TRANSFORM Study Group, Livingston; 2Novartis Pharmaceuticals Corporation, East Hanover.

    Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…
  • 2018 American Transplant Congress

    Immunoglobulin Replacement Therapy in Pediatric Renal Transplant Patients

    A. Lewis, M. Fasano, D. Zepeda-Orozco.

    University of Iowa Hospitals and Clinics, Iowa City, IA.

    Immunoglobulin replacement therapy decreases infection frequency in patients with primary immunodeficiency; however, there is limited data regarding the use of intravenous immunoglobulin (IVIG) or subcutaneous…
  • 2017 American Transplant Congress

    Effect of Everolimus-Based Immunosuppressive Regimen on New Onset of Diabetes After Kidney Transplantation – A 24 Month Subanalysis from the ELEVATE Study.

    H. Holdaas,1 S. Chadban,1 J. de Fijter,1 L. Rostaing,1 U. Mancilla,1 P. Lopez,2 G. Bader,2 J. Cruzado,1 M. van der Giet.1

    1ELEVATE Study Group, Oslo, Norway; 2Novartis Pharma AG, Basel, Switzerland

    Purpose: New onset diabetes after transplantation (NODAT) is a common metabolic complication which affects long-term patient survival and graft outcomes. Most of the immunosuppressive drugs…
  • 2017 American Transplant Congress

    First Report of Human Liver Transplantation After Normothermic Machine Perfusion (NMP) in the United States.

    Q. Liu, B. Soliman, G. Iuppa, A. Nassar, A. Hassan, T. Diago Uso, K. Hashimoto, F. Aucejo, M. Fujiki, B. Eghtesad, J. Cywinski, S. Irefin, J. Fung, K. Abu-Elmagd, C. Miller, C. Quintini.

    Cleveland Clinic, Cleveland

    NMP is a novel preservation method for liver grafts. We transplanted 10 human livers after NMP to test the safety and feasibility of NMP on…
  • 2017 American Transplant Congress

    We Wish This Would Never Happen Again! Implementation of an Adverse Event Review System to Improve the Safety of Pediatric Solid Organ Transplant (SOT) Patients.

    J. Gossett,1 M. Lake,1 J. Bucuvalas,2 A. Basu,1 L. Burkhart,1 L. Danziger-Isakov,1 A. Lorts.1

    1Solid Organ Transplant Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; 2Division of Gastroenterology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background: 50% of SOT centers are cited by CMS for inadequate review of adverse events (AE)s. AE reviews are inconsistently performed, rarely cover near misses…
  • 2017 American Transplant Congress

    IVIg+Rituximab Desensitization (DES) Combined with Alemtuzumab (ATZ) Induction Does Not Increase Risk for Viral Infections (VIs) and Associated Complications in HLA-Sensitized (HS) Kidney Transplant Patients (KTx Pts).

    S. Ge, B.-H. Shin, J. Mirocha, D. Thomas, M. Chu, E. Rodriguez, C. Chao, A. Petrosyan, O. Galera, A. Vo, J. Choi, A. Peng, J. Kahwaji, S. Jordan, M. Toyoda.

    Transplant Immunology Laboratory, Biostatistics Core and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

    Background: VIs represent significant morbidity factors in KTx pts. DES followed by KTx with ATZ induction increased successful Tx rates in HS pts, but may…
  • 2017 American Transplant Congress

    Five Year Outcomes with Alemtuzumab Induction Therapy in Elderly Renal Transplant Recipients.

    M. Casagrande, K. Cunningham, C. Tseng, C. D'Agostino, L. Wong, C. Richardson.

    Pharmacy, Northwestern Memorial Hospital, Chicago, IL

    Background:The elderly population (≥ 65 years) comprise one fourth of patients on the waiting list for renal transplantation. Alemtuzumab use has increased over the past…
  • 2017 American Transplant Congress

    Donor Derived Transmission Events in 2015-2016: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).

    C. Wolfe,1 M. Clark,2 S. Tlusty,2 D. Kaul,1 M. Michaels.1

    1DTAC, Richmond; 2United Network for Organ Sharing, Richmond

    The OPTN DTAC, a multidisciplinary committee, evaluates potential donor derived transmission events (PDDTE), including mostly infections (I) & malignancies (M), to assess for likelihood of…
  • 2017 American Transplant Congress

    A Phase-Two, Randomised, Placebo-Controlled Trial: Belimumab in Renal Transplantation Targets Naïve, Activated Memory and Antibody Producing B Cells Whilst Sparing Regulatory B Cells.

    G. Banham,1,2 S. Flint,3 N. Torpey,2 P. Lyons,1 D. Shanahan,3 A. Gibson,3 A.-M. O'Sullivan,2 R. Jones,1,2,3 L. Devey,3 A. Richards,3 L. Erwig,3 C. Savage,3 K. Smith,1,2 R. Henderson,3 M. Clatworthy.1,2

    1Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; 2Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; 3GlaxoSmithKline, Stevenage, United Kingdom

    This phase 2, double-blind, randomised controlled study (BEL114424) explores the safety and potential efficacy of addition of belimumab to standard of care in renal transplantation…
  • 2017 American Transplant Congress

    Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.

    M. Pereira,1 F. Silveira,2 G. Papanicolaou,3 A. Langston,4 R. Avery,5 A. Wijatyk,6 J. Wu,6 M. Boeckh,7 F. Marty,8 S. Villano.9

    1Columbia University Medical Center, New York, NY; 2University of Pittsburgh Medical Center, Pittsburgh, PA; 3Memorial Sloan Kettering Cancer Center, New York, NY; 4Winship Cancer Institute, Atlanta, GA; 5Johns Hopkins University, Baltimore, MD; 6Shire, Lexington, MA; 7Fred Hutchinson Cancer Research Center, Seattle, WA; 8Brigham and Women's Hospital, Boston, MA; 9Shire (At Time of Study), Wayne, PA

    Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 19
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences